

S2 Table. Univariate analysis of survival in sorafenib-treated patients with advanced-stage hepatocellular carcinoma

Variables	Univariate analysis		<i>P</i>
	Hazard ratio	95% CI	
Gender, male			
Absent	Reference		
Present	0.907	0.540–1.522	0.711
Age, >72 years			
Absent	Reference		
Present	0.733	0.493–1.091	0.126
HBV			
Absent	Reference		
Present	1.313	0.784–2.201	0.301
HCV			
Absent	Reference		
Present	0.683	0.452–1.033	0.071
Alcohol abuse			
Absent	Reference		
Present	1.200	0.679–2.121	0.529
ECOG-PS, >0			
Absent	Reference		
Present	1.936	1.282–2.922	0.002
Child–Pugh B			
Absent	Reference		
Present	2.400	1.561–3.690	<0.001
Status of intrahepatic lesions			
None	0.610	0.282–1.320	0.210
Without MVI	Reference		
With MVI	2.200	1.408–3.437	0.001
Maximum size of the intrahepatic lesion, >50 mm			
Absent	Reference		
Present	1.528	1.021–2.288	0.039
Number of intrahepatic lesions, >7			
Absent	Reference		
Present	2.281	1.522–3.418	<0.001
EHM			
Absent	Reference		
Present	0.787	0.508–1.221	0.787
AFP, >400 ng/mL			
Absent	Reference		
Present	1.418	0.954–2.106	0.084
Pre-treatment			
Absent	Reference		
Present	0.673	0.391–1.157	0.152
Stage progression process			
Progress directly from early stage	Reference		
Others	1.762	1.060–2.858	0.022
Average daily dose, ≤400 mg/day			
Absent	Reference		
Present	0.935	0.629–1.388	0.737

Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; ECOG-PS, Eastern Cooperative Oncology Group performance status; MVI, macrovascular invasion; EHM, extrahepatic metastasis; AFP, alpha-fetoprotein